CD200 and leukemia: Lancet et al. compared the activity of CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells, to the activity of 7 + 3 in older individuals with AML-MRC [161].